title: Design, synthesis and structure-activity relationships of zwitterionic spirocyclic compounds as potent CCR1 antagonists.
abstract: A series of zwitterionic spirocyclic compounds were synthesised. In vitro data revealed that these compounds were potent CCR1 antagonists. In particular, 2, 4, 11 and 20 inhibited CCR1 mediated chemotaxis of THP-1 cells in a functional assay.
authors.affiliation: Department of Medicinal Chemistry, Respiratory Inflammation and Autoimmunity Innovative Medicines, AstraZeneca R&D, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. nafizal.hossain@astrazeneca.com
authors.forename: Nafizal
authors.initials: N
authors.lastname: Hossain
authors.forename: Svetlana
authors.initials: S
authors.lastname: Ivanova
authors.forename: Åsa Sjöholm
authors.initials: ÅS
authors.lastname: Timén
authors.forename: Jonas
authors.initials: J
authors.lastname: Bergare
authors.forename: Tesfaledet
authors.initials: T
authors.lastname: Mussie
authors.forename: Lena
authors.initials: L
authors.lastname: Bergström
mesh_terms: D045744:Cell Line, Tumor; D002633:Chemotaxis / Q000187:drug effects; D015195:Drug Design; D006801:Humans; D011485:Protein Binding; D054389:Receptors, CCR1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013141:Spiro Compounds / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: D054389:Receptors, CCR1; D013141:Spiro Compounds